An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

NCT00903734 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancers

Interventions

DRUG: Erlotinib Hydrochloride (Tarceva)

Sponsor

M.D. Anderson Cancer Center